Merck & Co.’s initial Phase II/III waveLINE-003 data for zilovertamab vedotin (zilo-V) in diffuse large B-cell lymphoma (DLBCL) at the American Society of Clinical Oncology meeting in Chicago raised some questions from the presentation’s discussant about the small number of patients treated to date and the fact that they were not very heavily pretreated.
Key Takeaways
- Data from Merck’s Phase II/III study of zilo-V in DLBCL presented at ASCO showed improvements in overall response and complete response rates when added to...
The data presented on 30 May were from the first part of a two-part trial that compared zilo-V combined with rituximab (Roche’s Rituxan and biosimilars), gemcitabine and oxaliplatin (R-GemOx) against...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?